cyclin-d1 and Ventricular-Dysfunction--Left

cyclin-d1 has been researched along with Ventricular-Dysfunction--Left* in 3 studies

Other Studies

3 other study(ies) available for cyclin-d1 and Ventricular-Dysfunction--Left

ArticleYear
Targeted inactivation of Cerberus like-2 leads to left ventricular cardiac hyperplasia and systolic dysfunction in the mouse.
    PloS one, 2014, Volume: 9, Issue:7

    Previous analysis of the Cerberus like 2 knockout (Cerl2-/-) mouse revealed a significant mortality during the first day after birth, mostly due to cardiac defects apparently associated with randomization of the left-right axis. We have however, identified Cerl2-associated cardiac defects, particularly a large increase in the left ventricular myocardial wall in neonates that cannot be explained by laterality abnormalities. Therefore, in order to access the endogenous role of Cerl2 in cardiogenesis, we analyzed the embryonic and neonatal hearts of Cerl2 null mutants that did not display a laterality phenotype. Neonatal mutants obtained from the compound mouse line Cer2-/-::Mlc1v-nLacZ24+, in which the pulmonary ventricle is genetically marked, revealed a massive enlargement of the ventricular myocardium in animals without laterality defects. Echocardiography analysis in Cerl2-/- neonates showed a left ventricular systolic dysfunction that is incompatible with a long lifespan. We uncovered that the increased ventricular muscle observed in Cerl2-/- mice is caused by a high cardiomyocyte mitotic index in the compact myocardium which is mainly associated with increased Ccnd1 expression levels in the left ventricle at embryonic day (E) 13. Interestingly, at this stage we found augmented left ventricular expression of Cerl2 levels when compared with the right ventricle, which may elucidate the regionalized contribution of Cerl2 to the left ventricular muscle formation. Importantly, we observed an increase of phosphorylated Smad2 (pSmad2) levels in embryonic (E13) and neonatal hearts indicating a prolonged TGFβs/Nodal-signaling activation. Concomitantly, we detected an increase of Baf60c levels, but only in Cerl2-/- embryonic hearts. These results indicate that independently of its well-known role in left-right axis establishment Cerl2 plays an important role during heart development in the mouse, mediating Baf60c levels by exerting an important control of the TGFβs/Nodal-signaling pathway.

    Topics: Animals; Animals, Newborn; Cardiomyopathies; Cyclin D1; Female; Gene Expression Regulation, Developmental; Heart Ventricles; Hyperplasia; Intercellular Signaling Peptides and Proteins; Mice; Myocytes, Cardiac; Nodal Protein; Signal Transduction; Smad2 Protein; Transforming Growth Factor beta; Ventricular Dysfunction, Left

2014
Postinfarct treatment with oxytocin improves cardiac function and remodeling via activating cell-survival signals and angiogenesis.
    Journal of cardiovascular pharmacology, 2009, Volume: 54, Issue:6

    We investigated whether postinfarct treatment with oxytocin (OT) improves left ventricular (LV) function and remodeling via cardiac repair of myocardial ischemia-reperfusion injury.. Experiments were performed with 30 minutes of coronary occlusion and 2 or 14 days of reperfusion rabbit model of myocardial infarction. LV function and remodeling were significantly improved in the OT group. The infarct size was significantly reduced in the OT group. The number of CD31-positive microvessels was increased significantly in the OT group. There were no Ki67-positive myocytes in either group. The expression of the OT receptor, phosphorylated (p)-Akt protein kinase, p-extracellular signal-regulated protein kinase, p-enodthelial NO synthase, p-signal transducer and activator of transcription 3, vascular endothelial growth factor, B-cell lymphoma 2, and matrix metalloproteinase-1 (MMP-1) were markedly increased in the OT group days 2 and 14 post myocardial infarction.. Postinfarct treatment with OT reduces myocardial infarct size and improves LV function and remodeling by activating OT receptors and prosurvival signals and by exerting antifibrotic and angiogenic effects through activation of MMP-1, endothelial NO synthase, and vascular endothelial growth factor. These findings provide new insight into therapeutic strategies for ischemic heart disease.

    Topics: Animals; Blood Pressure; Cyclin D1; Disease Models, Animal; Echocardiography; Extracellular Signal-Regulated MAP Kinases; Heart; Heart Rate; Male; Matrix Metalloproteinase 1; Microvessels; Myocardial Infarction; Myocardium; Neovascularization, Physiologic; Nitric Oxide Synthase Type III; Oxytocin; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Proto-Oncogene Proteins c-akt; Rabbits; Receptors, Oxytocin; Signal Transduction; STAT3 Transcription Factor; Stroke Volume; Vascular Endothelial Growth Factor A; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling

2009
Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.
    Circulation, 2004, Nov-09, Volume: 110, Issue:19

    Inflammatory mechanisms have been proposed to be important in heart failure (HF), and cytokines have been implicated to add to the progression of HF. However, it is unclear whether such mechanisms are already activated when hypertrophied hearts still appear well-compensated and whether such early mechanisms contribute to the development of HF.. In a comprehensive microarray study, galectin-3 emerged as the most robustly overexpressed gene in failing versus functionally compensated hearts from homozygous transgenic TGRmRen2-27 (Ren-2) rats. Myocardial biopsies obtained at an early stage of hypertrophy before apparent HF showed that expression of galectin-3 was increased specifically in the rats that later rapidly developed HF. Galectin-3 colocalized with activated myocardial macrophages. We found galectin-3-binding sites in rat cardiac fibroblasts and the extracellular matrix. Recombinant galectin-3 induced cardiac fibroblast proliferation, collagen production, and cyclin D1 expression. A 4-week continuous infusion of low-dose galectin-3 into the pericardial sac of healthy Sprague-Dawley rats led to left ventricular dysfunction, with a 3-fold differential increase of collagen I over collagen III. Myocardial galectin-3 expression was increased in aortic stenosis patients with depressed ejection fraction.. This study shows that an early increase in galectin-3 expression identifies failure-prone hypertrophied hearts. Galectin-3, a macrophage-derived mediator, induces cardiac fibroblast proliferation, collagen deposition, and ventricular dysfunction. This implies that HF therapy aimed at inflammatory responses may need to be targeted at the early stages of HF and probably needs to antagonize multiple inflammatory mediators, including galectin-3.

    Topics: Animals; Animals, Genetically Modified; Aortic Valve Stenosis; Cardiomyopathy, Hypertrophic; Cell Division; Cyclin D1; Disease Progression; Extracellular Matrix; Fibroblasts; Galectin 3; Gene Expression Profiling; Gene Expression Regulation; Heart Failure; Humans; Macrophage Activation; Mice; Oligonucleotide Array Sequence Analysis; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Stroke Volume; Ventricular Dysfunction, Left

2004